Acarbose in the prevention of cardiovascular disease and hypertension in patients with impaired glucose tolerance

Evidence Summaries

Level of Evidence = A
Acarbose is effective in the prevention of cardiovascular events and hypertension in patients with impaired glucose tolerance.

In an international, multicentre trial 1 , 1429 patients with a mean age of 54.5 years and BMI 30.9 were randomized to receive either acarbose 100 mg 3 times a day or placebo. Decreasing prostprandial hyperglycemia with acarbose was associated with a 2.5% absolute risk reduction and a 49% relative risk reduction in the development of cardiovascular events (HR 0.51, 95% CI 0.28 to 0.95), and a 5.3% absolute risk reduction and 34% relative risk reduction in the incidence of new cases of hypertension (HR 0.66, 95% CI 0.49 to 0.89). The risk reduction was no influenced by adjusting for major risk factors.

References

1. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 Jul 23;290(4):486-94.  [PMID:12876091]


Copyright © 2021 Duodecim Medical Publications Limited.
Acarbose in the prevention of cardiovascular disease and hypertension in patients with impaired glucose tolerance is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or .

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. .